



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

STUDIES ON THE MODE OF ACTION OF THE ANTITUMOUR ACRIDINE
4'-(9-ACRIDINYLAMINO)METHANESULPHON-*m*-ANISIDIDE (*m*-AMSA)

A thesis submitted to the
University of Auckland
for the degree of
Doctor of Philosophy

by

William R. Wilson

Department of Cell Biology
University of Auckland

March, 1978

"Too much trust should not be put in an experiment
done with the object of getting information."

W.D. Bancroft (1928)

TABLE OF CONTENTS

ACKNOWLEDGEMENTS	1
SUMMARY	2
SYMBOLS AND ABBREVIATIONS	4
Chapter One	
TOWARDS A RATIONAL CANCER CHEMOTHERAPY	8
1.1 INTRODUCTION	8
1.2 THE DEVELOPMENT OF CANCER CHEMOTHERAPY	8
1.3 PRINCIPLES OF CANCER CHEMOTHERAPY	10
1.3.1 <i>PROBLEMS IN OBTAINING CURE BY CHEMOTHERAPY</i>	10
1.3.2 <i>BASES OF SELECTIVE TOXICITY</i>	12
(a) Selectivity Based on Cell Proliferation Kinetics	13
(b) Selectivity based on Differential Exposure of Normal and Neoplastic Cells to Cytotoxic Drugs	18
1.3.3 <i>MECHANISMS OF CELL KILLING BY ANTITUMOUR DRUGS</i>	25
(a) DNA Chauvanism	27
(b) Mechanism of Cell Killing by Drugs Acting on DNA	28
1.4 STRATEGY IN DRUG DESIGN	33
1.5 BIOLOGICAL EFFECTS OF ACRIDINES	40
1.5.1 <i>MUTAGENESIS AND CARCINOGENESIS</i>	40
1.5.2 <i>ANTIVIRAL ACTION</i>	42
1.5.3 <i>ANTIBACTERIAL ACTION</i>	42
1.5.4 <i>ANTIMALARIAL ACTION</i>	43
1.5.5 <i>ANTITUMOUR ACTION</i>	44

1.6 DEVELOPMENT OF THE AMSA SERIES	46
1.6.1 ORIGIN OF THE AMSA SERIES	46
1.6.2 STRUCTURE-ACTIVITY RELATIONSHIPS	48
1.6.3 ADJUSTMENT OF NET LIPOPHILICITY	51
1.6.4 PROBLEMS WITH DISTRIBUTION	52
1.6.5 PRESENT STATUS	53
1.6.6 OTHER 9-ANILINOACRIDINES	54
1.7 SHORT REVIEW OF THE CURRENT LITERATURE ON AMSA COMPOUNDS	55
1.8 SCOPE OF THE PRESENT STUDY	59
 Chapter Two	
MATERIALS	62
2.1 BIOLOGICAL MATERIALS	62
2.1.1 MICE	62
2.1.2 TUMOUR CELLS	62
2.1.2 BACTERIA	62
2.1.4 BACTERIOPHAGE T ₄ CONTAINING [³ H]DNA	62
2.2 ACRIDINES	63
2.2.1 AMSA DRUGS	63
2.2.2 OTHER ACRIDINES	63
2.3 RADIOCHEMICALS	64
2.3.1 [acridinyl-G- ³ H]AMSA COMPOUNDS	64
2.3.2 [phenyl-G- ³ H]AMSA	66
2.3.3 OTHER RADIOCHEMICALS	66
2.4 LIQUID SCINTILLATION COCKTAILS	67
2.5 BUFFERS	67
2.5.1 SHE BUFFERS	67
2.5.2 PBS	67
2.5.3 SBSS	67
2.5.4 TRIETHYLAMMONIUM BICARBONATE	67
2.6 CULTURE MEDIA AND SUPPLEMENTS	67
2.7 NUCLEIC ACIDS	68
2.8 CHROMATOGRAPHIC MATRICES	68

2.9 SOLVENTS	68
2.10 OTHER CHEMICALS	68
2.11 MISCELLANEOUS MATERIALS	70
 Chapter Three	
DISTRIBUTION AND METABOLISM OF AMSA DRUGS	71
3.1 INTRODUCTION	71
3.2 METHODS	75
3.2.1 BLOOD AND BLOOD PLASMA	75
3.2.2 THIN LAYER CHROMATOGRAPHY	75
3.2.3 GEL EXCLUSION CHROMATOGRAPHY	75
3.2.4 ESTIMATION OF PROTEIN	76
3.2.5 ESTIMATION OF THIOLS	76
3.2.6 PREPARATION OF THE PROTEIN ADDUCT FORMED FROM <i>m</i> -AMSA IN BLOOD	76
3.2.7 CARBOXYMETHYLATION OF SERUM PROTEINS	76
3.2.8 SPECTROPHOTOMETRY	77
3.2.9 SPECTROFLUORIMETRY	77
3.2.10 MEASUREMENT OF RADIOACTIVITY	77
3.3 RESULTS AND DISCUSSION	78
3.3.1 THE DISTRIBUTION AND METABOLISM OF AMSA COMPOUNDS IN THE MOUSE	78
(a) <i>m</i> -AMSA has a Short Half-Life in Blood Plasma Relative to its Biotransformation Product	78
(b) Biotransformation Products in Plasma are Associated with Proteins	79
(c) <i>o</i> -AMSA does not Distribute as Readily as <i>m</i> -AMSA from the S.C. Injection Site	80
3.3.2 THE BIOTRANSFORMATION OF AMSA DRUGS IN MOUSE BLOOD IN VITRO	80
(a) Biotransformation Occurs in Isolated Blood	80
(b) The Reaction is Facilitated by Blood Cells	82
(c) The Biotransformation Reaction Occurs in Several Other Systems	82
3.3.3 EVIDENCE FOR THE FORMATION OF COVALENT ACRIDINE- PROTEIN ADDUCTS BY NUCLEOPHILIC DISPLACEMENT OF THE METHANESULPHONANILIDE MOIETY	83

(a) The Biotransformation Product is a Protein Adduct Containing a Covalently Bound Acridine Ring	83
(b) The Methanesulphonanilide Moiety is Displaced During the Reaction	84
3.3.4 EVIDENCE THAT THE DISPLACING GROUP IN THE BIOTRANSFORMATION REACTION IS A THIOL	86
(a) The Rate of Biotransformation of AMSA Drugs is Correlated with Their Reactivity Towards Mercaptoethanol	86
(b) Attempts to Identify Acridinylated Amino Acids Obtained by Hydrolysis of the Protein Adduct	87
(c) The Rate of Hydrolysis of the Adduct to 9-Acridanone Resembles That for 9-Ethylthioacridine	88
(d) The Fluorescence Emission Spectrum of the Protein Adduct does not Correspond to Model 9-Substituted Acridines	88
(e) The Reaction of AMSA with Calf Serum Proteins is Blocked by Carboxymethylation of Protein Thiols	89
(f) The Free Thiol Content of Plasma Decreases During Formation of Protein Adducts	90
3.4 CONCLUSIONS	90
 Chapter Four	
EFFECTS OF <i>m</i> -AMSA ON TUMOUR CELLS <i>IN VIVO</i>	95
4.1 INTRODUCTION	95
4.2 METHODS	97
4.2.1 GROWTH OF TUMOUR CELLS <i>IN VIVO</i>	97
4.2.2 MEASUREMENT OF CELL DENSITY	97
4.2.3 TRYPAN BLUE TEST FOR CELL VIABILITY	98
4.2.4 MEASUREMENT OF ACID-INSOLUBLE RADIOACTIVITY FOLLOWING [³ H]TdR LABELLING	98
4.2.5 RECOVERY OF BONE MARROW AND SPLEEN CELLS FROM MICE	98
4.3 RESULTS AND DISCUSSION	99

4.3.1	<i>EFFECTS ON THE L1210 LEUKAEMIA IN VIVO</i>	99
	(a) Measurement of DNA Synthesis <i>In Vivo</i>	99
	(b) Effects of <i>m</i> -AMSA on TdR Incorporation and Cell Number <i>In Vivo</i>	101
4.3.2	<i>ANTITUMOUR EFFECTS OF AMSA DRUGS IN MICE BEARING MASTOCYTOMA P815</i>	103
4.4	CONCLUSIONS	104
4.5	APPENDIX	106

Chapter Five

	DEVELOPMENT OF A TISSUE CULTURE MODEL FOR THE ANTITUMOUR ACTION OF AMSA DRUGS	107
5.1	INTRODUCTION	107
5.2	METHODS	108
	5.2.1 <i>TISSUE CULTURE TECHNIQUES</i>	108
	5.2.2 <i>MEASUREMENT OF CELL DENSITY AND VIABILITY</i>	109
	5.2.3 <i>MEASUREMENT OF UPTAKE OF [acridinyl-G-³H]AMSA DRUGS BY MASTOCYTOMA CELLS</i>	109
5.3	RESULTS AND DISCUSSION	110
	5.3.1 <i>CULTURE CONDITIONS FOR MASTOCYTOMA CELLS</i>	110
	5.3.2 <i>ACUTE CYTOTOXICITY OF AMSA DRUGS</i>	111
	5.3.3 <i>GROWTH INHIBITION BY AMSA DRUGS</i>	112
	(a) Continuous Exposure	112
	(b) Pulse exposure	113
	5.3.4 <i>BIOTRANSFORMATION OF [acridinyl-G-³H]AMSA DRUGS IN MASTOCYTOMA CULTURES</i>	115
	5.3.5 <i>UPTAKE OF [acridinyl-G-³H]AMSA DRUGS BY MASTOCYTOMA CELLS</i>	117
	(a) Uptake of [acridinyl-G- ³ H] <i>m</i> -AMSA	117
	(b) Comparison of Uptake of AMSA, <i>o</i> -AMSA and <i>m</i> -AMSA	119
5.4	CONCLUSIONS	121

Chapter Six	
EFFECTS OF AMSA DRUGS ON THE PROGRESSION OF MASTOCYTOMA CELLS THROUGH THE CELL CYCLE	125
6.1 INTRODUCTION	125
6.2 METHODS	127
6.2.1 MEASUREMENT OF CELL VOLUME DISTRIBUTIONS AND MEAN CELL VOLUMES WITH A COULTER COUNTER	127
6.2.2 MEASUREMENT OF VISCOSITY AND DENSITY OF CULTURE MEDIA	128
6.2.3 DETERMINATION OF MITOTIC INDEX	129
6.2.4 VELOCITY SEDIMENTATION OF MASTOCYTOMA CELLS	130
6.2.5 ALKALINE SUCROSE GRADIENT ANALYSIS OF DNA FROM MASTOCYTOMA CELLS	130
6.3 RESULTS AND DISCUSSION	131
6.3.2 EFFECTS OF AMSA DRUGS ON CELL VOLUME DISTRIBUTION AND MEAN CELL VOLUME	131
(a) Volume Distribution of Cultured Cells	131
(b) Effects of AMSA Drugs	132
6.3.2 EFFECTS OF m-AMSA ON ENTRY INTO MITOSIS	134
6.3.3 EFFECTS OF AMSA DRUGS ON [³ H]TdR INCORPORATION	136
(a) [³ H]TdR Metabolism in Mastocytoma Cell Cultures	136
(b) Effects of AMSA Drugs	138
6.3.4 CELL CYCLE STAGE SPECIFICITY OF THE CYTOSTATIC ACTION OF AMSA DRUGS	139
(a) Rationale for the Velocity Sedimentation/ Subculture (VSS) Method	139
(b) Effect of Seeding Density on the Growth Kinetics of Mastocytoma P815	140
(c) VSS Analysis of Untreated Mastocytoma Cells	141
(d) Evaluation of the VSS Method Using Known S- Phase-Specific Cytotoxic Agents	142
(e) Determination of the Cell-Cycle-Stage Specificity of AMSA Drugs by the VSS Method	143
6.3.5 EFFECTS OF TREATMENT WITH m-AMSA ON THE STRUCTURAL INTEGRITY OF MASTOCYTOMA CELL DNA	144
6.4 CONCLUSIONS	147

6.5 APPENDIX I. MEAN CELL VOLUME OF MASTOCYTOMA P815 CELLS	150
6.5.1 ESTIMATION OF MEAN CELL VOLUME WITH A COULTER COUNTER	150
(a) Absolute Calibration	150
(b) Haematological Calibration	151
6.5.2 ESTIMATE OF MEAN CELL VOLUME FROM SEDIMENTATION VELOCITY	152
6.5.3 ESTIMATE OF MEAN CELL VOLUME USING PACKING OF CELLS BY CENTRIFUGATION	154
6.6 APPENDIX II. RADIOTOXICITIES OF [³ H]- AND [¹⁴ C]TdR IN MASTOCYTOMA CELL CULTURES	157
6.6.1 EFFECTS OF [³ H]TdR ON GROWTH AND RATES OF EXOGENOUS TdR INCORPORATION	157
6.6.2 EFFECTS OF [¹⁴ C]TdR ON GROWTH OF MASTOCYTOMA CELLS	159
6.6.3 COMPARISON OF THE SEDIMENTATION BEHAVIOUR IN ALKALI OF DNA LABELLED WITH [³ H]- AND [¹⁴ C]TdR	159

Chapter Seven

THE INTERACTION OF <i>m</i> -AMSA AND RELATED COMPOUNDS WITH NUCLEIC ACIDS	162
7.1 INTRODUCTION	162
7.1.1 NON-COVALENT INTERACTIONS OF DRUGS WITH NUCLEIC ACIDS	162
7.1.2 DESCRIPTION OF BINDING EQUILIBRIA	163
(a) Analysis of Binding Data	163
(b) Methods for Measuring Free and Bound Ligand Concentrations	169
(c) Available Descriptions of Binding Isotherms for Acridines	171
7.1.3 THE STRUCTURE OF ACRIDINE:DNA COMPLEXES	176
(a) Evidence for Intercalation	176
(b) Stereochemistry of Intercalation Complexes	178
7.1.4 EFFECTS OF ACRIDINES ON THE TEMPLATE ACTIVITY OF DNA	182
7.1.5 DNA AS A RECEPTOR FOR THE BIOLOGICAL EFFECTS OF ACRIDINES	186
7.1.6 BACKGROUND AND SCOPE OF THE PRESENT STUDY	191

7.2 METHODS	194
7.2.1 NUCLEIC ACIDS	194
7.2.2 MEASUREMENT OF THE EFFECTS OF NUCLEIC ACIDS ON THE VISIBLE ABSORPTION SPECTRA OF THE DRUGS	194
7.2.3 CALCULATION OF BINDING PARAMETERS FROM SPECTROPHOTOMETRIC TITRATIONS	195
7.2.4 MEASUREMENTS OF THE EFFECTS OF DRUGS ON THE THERMAL DENATURATION OF DNA	196
7.3 RESULTS	197
7.3.1 SELECTION OF BUFFERS	197
7.3.2 VISIBLE ABSORPTION SPECTRA OF DRUGS	198
7.3.3 SPECTRAL CHANGES INDUCED BY NUCLEIC ACIDS	198
7.3.4 SPECTROPHOTOMETRIC DETERMINATIONS OF BINDING PARAMETERS	199
(a) Interaction with Native CT DNA in 0.01 SHE	199
(b) Interaction of <i>o</i> - and <i>m</i> -AMSA with Native CT DNA at Higher Ionic Strength	200
(c) Interaction with Denatured CT DNA	200
(d) Interaction with TYMV RNA	202
7.3.5 EFFECTS ON THE THERMAL DENATURATION OF DNA	203
7.4 DISCUSSION	204
7.4.1 SPECTRAL CHANGES INDUCED BY NUCLEIC ACIDS	204
7.4.2 BINDING TO NATIVE CT DNA	205
7.4.3 BINDING TO DENATURED CT DNA AND TYMV RNA	208
7.4.4 EFFECTS ON THE STABILITY OF THE DOUBLE HELIX	211
7.4.5 MODEL BUILDING	212
7.4.6. THE BIOLOGICAL SIGNIFICANCE OF BINDING TO NUCLEIC ACIDS	215
7.5 CONCLUSIONS	220
7.6 APPENDIX. THE CHOICE OF LATTICE UNIT IN THE MCGHEE AND VON HIPPEL MODEL	222
7.6.1 THE DEFINITION OF "FREE SITE", AND ITS IMPLICATION IN THE CHOICE OF LATTICE UNIT	222
7.6.2 THE EFFECT OF CHOICE OF LATTICE UNIT ON THE CURVATURE OF THE SCATCHARD PLOT	224

Chapter Eight	
CONCLUDING DISCUSSION	228
8.1 THE MECHANISM OF ACTION OF <i>m</i> -AMSA	228
8.2 FACTORS DETERMINING THE ACTIVITY OF AMSA DRUGS	231
8.3 A COMPARISON OF <i>m</i> -AMSA WITH ADRIAMYCIN	234
8.4 FURTHER WORK	237
BIBLIOGRAPHY	243
ERRATA	267
PUBLICATIONS	

ACKNOWLEDGEMENTS

I wish to thank Dr Bruce Baguley for his enlightened supervision of this study, his enthusiasm and his personal friendship. I feel bound to attest his unique qualities as a teacher, and in particular the humanity with which he has approached this difficult task.

Dr Bruce Cain, Dr Bill Denny and Mr Graeme Attwell of the Cancer Chemotherapy Laboratory, Cancer Society of N.Z., have played an essential part in this study. I wish to thank them for generous provision of materials, for free access to unpublished data, and for many stimulating discussions. I have come to respect not only their ability, but also their dedication to cancer chemotherapy. I also wish to acknowledge my indebtedness to Dr Michael Waring of the Department of Pharmacology, University of Cambridge, for invaluable arguments and discussions on the DNA binding studies. I have learned much from our brief encounters.

I owe a debt to the staff of the Cell Biology Department for their assistance and advice with many problems encountered in this study, and for tolerating my extramural activities. In particular I wish to thank Professor Ray Ralph for his provision of tissue culture facilities and interest in this work, and Mrs Ellen-Marie Falkenhaus for assistance with the mitotic index determinations.

To Lynda, who tried to ignore the whole performance and almost succeeded, and to my children who waited patiently through the long days of thesis preparation, I give my love. I acknowledge that they and my close friends have shared in the costs, but not in the rewards, of experimental science.

Above all, I want to thank Jude Meikle for her encouragement, help and personal friendship throughout all phases of this work. She is the secret coauthor of this study. My debt to her extends from expert technical help with the development of the VSS method, to long nights on the typewriter. If I have emerged from this ordeal with my sanity preserved (which remains to be determined) it is because of her.

SUMMARY

- (1) The mode of action of a novel antitumour acridine 4'-(9-acridinylamino)-methanesulphon-*m*-anisidide (*m*-AMSA) has been investigated. Two congeners of *m*-AMSA, 4'-(9-acridinylamino)methanesulphonanilide (AMSA) and 4'-(9-acridinylamino)methanesulphon-*o*-anisidide (*o*-AMSA) were also studied for comparative purposes. *m*-AMSA is being evaluated clinically at present under the auspices of the National Cancer Institute, U.S.A.
- (2) Treatment of mice bearing the mast cell tumour, mastocytoma P815, with *m*-AMSA provided some complete cures. AMSA was almost as effective as *m*-AMSA but its dose potency was 6-fold lower. *o*-AMSA was inactive.
- (3) *m*-AMSA was found to have a short half-life in mice. Loss of *m*-AMSA from plasma was due, in part, to the formation of highly fluorescent covalent protein adducts. The rate of this reaction was similar for all three AMSA congeners, and is probably not required for antitumour activity.
- (4) The reaction of AMSA drugs with proteins was shown to occur by nucleophilic displacement of the methanesulphonanilide moiety. Evidence is presented that thiols are the predominant reaction centres in proteins.
- (5) A tissue culture model for the antitumour action of *m*-AMSA was developed using mastocytoma P815 cells. Profound growth inhibition and eventual killing was demonstrated using drug concentrations and durations of exposure attainable in mice. The potencies of the three AMSA congeners paralleled their antitumour potencies *in vivo*, except at very high drug concentrations.
- (6) The rates of biotransformation of AMSA drugs, and their extent of uptake by cells in culture, could not account for the differing potencies of the three AMSA congeners.
- (7) *m*-AMSA prevented the progression of mastocytoma cells through the cell division cycle under conditions where net cell growth was unaffected.

Physiologically attainable drug concentrations inhibited chromosome condensation in cells which were less than 10 minutes from the G₂-phase/mitosis boundary at the time of drug addition. The sedimentation rate on alkaline sucrose gradients of DNA from cells treated with *m*-AMSA was lower than that from untreated cells, suggesting that this agent may cause fragmentation of DNA.

- (8) A new method for the investigation of the cell cycle stage selectivity of antitumour drugs was developed. This technique demonstrated that *m*-AMSA and AMSA have significant cycle stage selectivity, the growth of cells late in cycle being most affected.
- (9) Spectrophotometric determinations of binding parameters for the interaction of AMSA derivatives with native DNA indicated that *m*-AMSA bound with lower affinity than did *o*-AMSA or AMSA. This conclusion was supported by the helix stabilization caused by these drugs. However, the association constants were sufficiently high for each derivative to ensure that essentially all intracellular drug available for binding to DNA would be bound.
- (10) The ratio of the association constant for native DNA to that for a single-stranded viral RNA was higher for *m*-AMSA than for AMSA. This selectivity, if operative *in vivo*, could account for the high dose potency of *m*-AMSA.

SYMBOLS AND ABBREVIATIONS

A	amplification factor (Coulter Counter)
9-AA	9-aminoacridine
[acridinyl-G- ³ H]AMSA	AMSA randomly labelled (³ H) in the acridine ring
[acridinyl-G- ³ H] <i>m</i> -AMSA	<i>m</i> -AMSA randomly labelled (³ H) in acridine ring
[acridinyl-G- ³ H] <i>o</i> -AMSA	<i>o</i> -AMSA randomly labelled (³ H) in acridine ring
AMSA	4'-(9-acridinylamino)methanesulphonanilide
Ara-C	1-β-D-arabinofuranosylcytosine
A _x	absorbance at wavelength x(nm)
BCNU	1,3-bis(2-chloroethyl)-1-nitrosourea
BSA	bovine serum albumin
C _b	concentration of bound ligand
C _f	concentration of free ligand
Ci	curie
CM-protein	carboxymethylated protein
cpm	counts per minute
[¹⁴ C]TdR	[2- ¹⁴ C]thymidine
CT DNA	deoxyribonucleic acid from calf thymus
DNA	deoxyribonucleic acid
dpm	disintegrations per minute
DTNB	5,5'-dithiobis(2-nitrobenzoic acid)
DTT	dithiothreitol
F	aperture current factor (Coulter Counter)
3'-F-AMSA	4'-(9-acridinylamino)methanesulphon- <i>m</i> -fluoro- anilide
fl	femtolitre
fu	unit of fluorescence intensity
g	gram, or gravitational acceleration
h	hour
HEPES	N-2-hydroxyethylpiperazine-N'-2-ethanesulphonic acid
HU	hydroxyurea
i.c	intracerebral
i.p.	intraperitoneal

i.v.	intravenous
k	calibration factor (Coulter Counter)
K_e	association constant for a single lattice residue
K_s	association constant for a site defined by the saturation binding ratio
kg	kilogram
LD_{10}	dose of drug which is lethal to 10% of the test organisms
LDS	lithium dodecyl sulphate
LFER	linear free energy relationship
m	metre (unless otherwise defined)
M	molar
<i>m</i> -AMSA	4'-(9-acridinylamino)methanesulphon- <i>m</i> -anisidide
3'-Me-AMSA	4'-(9-acridinylamino)methanesulphon- <i>m</i> -toluidide
MeOH	methanol
mCi	millicurie
mg	milligram
min	minute
min.	minimum
ml	millilitre
mol	mole
mmol	millimole
n	nucleic acid binding site size, in nucleotides
n'	nucleic acid binding site size, in base pairs
N	nucleic acid concentration in nucleotide residues (unless otherwise defined)
N_i	number of pulses in the <i>i</i> th channel
nm	nanometre
nM	nanomolar
nmol	nanomole
NNCS	neonatal calf serum
<i>o</i> -AMSA	4'-(9-acridinylamino)methanesulphon- <i>o</i> -anisidide
P	partition coefficient
PBS	phosphate-buffered saline
PF	proflavine
pg	picogram

[phenyl-G- ³ H]AMSA	AMSA randomly labelled (³ H) in the phenyl ring
pmol	picomole
POPOP	1,4-bis[2-(5-phenyloxazolyl)]-benzene; phenyl-oxazolylphenyl-oxazolylphenyl
PPO	2,5-diphenyloxazole
q.d.	daily administration
QSAR	quantitative structure-activity relationship
r	radius
r	binding ratio (unless otherwise defined)
R _f	chromatographic mobility
RNA	ribonucleic acid
rpm	revolutions per minute
s	second
SBSS	Shortman's balanced salt solution
s.c.	subcutaneous
S.D.	standard deviation
S _f	concentration of free (unoccupied) ligand binding sites
SHE	buffer (saline-HEPES-EDTA)
t	elapsed time
T	sedimentation time
T _{1/2}	half-life (unless otherwise defined)
T _g	cell generation time
TCA	Trichloroacetic acid
TdR	thymidine
TLC	thin layer chromatography
tris	tris(hydroxymethyl)aminomethane
TYMV	turnip yellow mosaic virus
uv	ultraviolet
\bar{V}	mean cell volume
V _m	volume of medium in wet pellet
V _c	volume of cells in wet pellet
w/v	weight per volume
v/v	volume per volume
α	number of ligand binding sites per lattice residue
δ ₁	channel number
ε	molar extinction coefficient

$\Delta\epsilon$	differential molar extinction coefficient
η	absolute viscosity
λ	wavelength
λ_i	wavelength of an isobestic point
λ_m	wavelength at maximum of difference spectrum
μ	ionic strength
μCi	microcurie
μg	microgram
μl	microlitre
μM	micromolar
μmol	micromole
v	binding ratio (mol ligand/mol base pairs)
v_L	binding ratio (mol ligand/mol lattice residues)
ρ	absolute density of cells
ρ_o	absolute density of solution
ρ_w	absolute density of water
σ_m	Hammett substituent constant (meta)
σ_p	Hammett substituent constant (para)
ϕ	cell volume fraction
ω	mitotic index